JPRN-jRCT2080220498未知1 期
A Phase I, Open Label, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1152 in Japanese Patients With Acute Myeloid Leukaemia
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 20 Years and older
- •Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Subjects must be in first, second or third relapse at least one month after completion of initial course of induction and consolidation therapy (may include autologous transplant but not allogenic stem cell transplantation)
- •- Newly diagnosed Acute Myeloid Luekimia who are not considered suitable for other treatments.
排除标准
- •- Previous myeloablative therapy with autologous or allogenic bone marrow or stem cell transplantation, radiotherapy or chemotherapy within 4 weeks of first dose.
- •- Participation in any other trial with an investigational product within the previous 30 days.
- •- Other active malignancy.
研究者
相似试验
招募中
1 期
Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumorsSolid tumorJPRN-jRCT2041220034Yasuhiro Koh3
未知
1 期
A Phase 1, Open-Label, Multi-center Study to Assess the Safety and Tolerability of AZD6244 (Selumetinib, ARRY142886) in Combination With Cisplatin/Gemcitabine in Japanese Patients With Inoperable Locally Advanced or Metastatic Biliary Tract Cancer (BTC)Inoperable Locally Advanced or Metastatic Biliary Tract CancerJPRN-jRCT2080222349AstraZeneca
已完成
不适用
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients with Metastatic Castration-Resistant Prostate Cancercastrate-resistant prostate cancer10038597Prostate CancerNL-OMON34099Astra Zeneca17
进行中（未招募）
1 期
Open-label study to assess the PK and safety of naloxegol in paediatric patients receiving opioidsEUCTR2013-003935-32-NOKyowa Kirin Pharmaceutical Development Ltd.48
进行中（未招募）
1 期
Open-label study to assess the PK and safety of naloxegol in paediatric patients receiving opioidsEUCTR2013-003935-32-GBKyowa Kirin Pharmaceutical Development Ltd.48